Aligos Therapeutics (ALGS) AI Stock Analysis

• Market Cap: $44.35M
• Dividend Yield: N/A
• Average Volume (3M): 86.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.68
• Revenue Growth: -55.88%
• EPS Growth: 6.14%
• Country: US
• Employees: 70
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.04
• Shares Outstanding: 5,351,374
• 10 Day Avg. Volume: 122,947
• 30 Day Avg. Volume: 86,969
• PEG Ratio: >-0.01
• Price to Book (P/B): -8.61
• Price to Sales (P/S): 63.27
• P/FCF Ratio: -3.09
• Enterprise Value/Market Cap: -0.94
• Enterprise Value/Revenue: -21.81
• Enterprise Value/Gross Profit: -42.61
• Enterprise Value/Ebitda: 0.50
• 1Y Price Target: $50.00
• Price Target Upside: 604.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $7.00 ▼(-1.41% Downside)

Aligos Therapeutics' overall stock score is primarily impacted by its poor financial performance, characterized by consistent losses and negative cash flows. The technical analysis indicates a bearish trend with oversold conditions, while the valuation reflects ongoing unprofitability. These factors collectively result in a low stock score, highlighting significant risks and challenges facing the company.

Positive Factors

Proprietary Technology Platforms

Aligos' proprietary technology platforms enable the development of novel therapeutics, providing a competitive edge in addressing unmet medical needs in viral infections and liver diseases.

Low Leverage

Low leverage indicates financial prudence, allowing Aligos to navigate industry challenges with greater flexibility and reduced risk of financial distress.

Regulatory Advancement

The adoption of a nonproprietary name for ALG-000184 marks a significant regulatory milestone, potentially accelerating the drug's path to market and enhancing Aligos' competitive position.

Negative Factors

Consistent Losses

Ongoing financial losses highlight operational inefficiencies and pose a threat to long-term sustainability, requiring strategic improvements for future profitability.

Negative Cash Flows

Negative cash flows limit Aligos' ability to reinvest in R&D and growth initiatives, potentially hindering its capacity to capitalize on market opportunities and sustain operations.

Declining Revenue Trend

A declining revenue trend indicates challenges in market penetration and product adoption, necessitating strategic efforts to reverse the trend and ensure long-term growth.

Aligos Therapeutics Business Overview & Revenue Model

Company Description

Aligos Therapeutics (ALGS) is a biotechnology company focused on developing innovative therapies for viral infections and liver diseases. The company primarily operates in the biopharmaceutical sector, with a particular emphasis on hepatitis B and other liver-related conditions. Aligos is known for its proprietary technology platforms that facilitate the discovery and development of novel therapeutics aimed at addressing unmet medical needs in these areas.

How the Company Makes Money

Aligos Therapeutics generates revenue through several key streams. Primarily, the company engages in research and development collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments based on the achievement of specific clinical or regulatory objectives, and royalties on future sales of products developed from these partnerships. Additionally, Aligos may receive funding from government grants or awards aimed at supporting innovative research in the biotech space. The company may also generate revenue through the licensing of its proprietary technologies or drug candidates to other firms in exchange for fees and royalties, enhancing its financial stability and growth prospects.

Aligos Therapeutics Financial Statement Overview

Summary

Aligos Therapeutics faces significant financial challenges, with consistent losses and negative cash flows. While the company maintains low leverage, its profitability and cash flow generation are concerning. The biotechnology industry often involves high R&D costs, which may contribute to these financial difficulties. Strategic improvements in operational efficiency and revenue growth are essential for future stability.

Income Statement

Aligos Therapeutics shows a declining revenue trend with a negative revenue growth rate of -2.94% in the TTM. The company has consistently negative net profit margins, with the latest at -23.37%, indicating ongoing losses. Gross profit margins are relatively high at 70.70%, but the negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.07, suggesting limited leverage, which is a positive aspect. However, the return on equity is significantly negative at -123.93%, reflecting poor profitability relative to shareholder equity. The equity ratio is stable, indicating a reasonable proportion of equity financing.

Cash Flow

Aligos Therapeutics has negative operating and free cash flows, with a slight decline in free cash flow growth of -4.92% in the TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is slightly better than net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.91M	3.94M	15.53M	13.91M	4.36M	0.00
Gross Profit	975.00K	3.94M	12.46M	10.23M	-99.79M	-3.33M
EBITDA	-82.41M	-86.53M	-85.06M	-93.91M	-124.54M	-105.06M
Net Income	-86.46M	-131.21M	-87.68M	-96.05M	-128.33M	-108.54M
Balance Sheet
Total Assets	109.76M	70.09M	151.53M	146.69M	235.37M	265.30M
Cash, Cash Equivalents and Short-Term Investments	99.10M	56.94M	135.70M	125.83M	190.73M	243.51M
Total Debt	6.07M	8.38M	11.14M	12.57M	14.46M	13.01M
Total Liabilities	37.93M	99.07M	59.45M	42.79M	50.64M	45.26M
Stockholders Equity	71.83M	-28.97M	92.08M	103.90M	184.73M	220.04M
Cash Flow
Free Cash Flow	-79.53M	-80.87M	-79.02M	-80.33M	-116.55M	-76.33M
Operating Cash Flow	-79.16M	-80.74M	-79.00M	-79.39M	-115.66M	-74.26M
Investing Cash Flow	-15.83M	-18.28M	44.98M	-26.29M	3.02M	32.76M
Financing Cash Flow	101.61M	355.00K	88.33M	164.00K	78.68M	192.35M

Aligos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Negative. The current price of 7.1 is below the 20-day moving average (MA) of 9.02, below the 50-day MA of 9.70, and below the 200-day MA of 10.14, indicating a bearish trend. The MACD of -0.73 indicates Positive momentum. The RSI at 28.77 is Positive, neither overbought nor oversold. The STOCH value of 19.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALGS.

Aligos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRNS	43 Neutral	$45.19M	―	-53.78%	―	―	-5.42%
ALGS	38 Underperform	$44.35M	-0.36	-141.82%	―	-55.88%	6.14%
CELU	38 Underperform	$45.91M	-0.54	-6367.24%	―	4.45%	45.19%
ACRV	36 Underperform	$62.91M	―	-47.87%	―	―	18.86%

Aligos Therapeutics Corporate Events

Aligos Therapeutics’ Promising Hepatitis B Study: A Potential Game-Changer?

Study Overview: Aligos Therapeutics, Inc. is conducting a Phase 2 study titled ‘A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)’. The study aims to assess the efficacy and safety of ALG-000184, a potential new treatment for chronic Hepatitis B, compared to the existing treatment, Tenofovir Disoproxil Fumarate (TDF). This study is significant as it could lead to improved treatment options for patients with chronic Hepatitis B.

Aligos Therapeutics Reports Q2 2025 Progress and Results

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing advanced therapies for liver and viral diseases, with a focus on chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.